Greater availability of human reagents in the near future should greatly aid in resolving the identity of the cell-types involved.
A titration of recombinant peptide corresponding to amino acids 20-128 of mouse ANG-1 (Primm, Cambridge, MA) was used to gauge the specificity to mouse ANG-1, and was appropriately detected by the human reagents.
All human reagents are also reactive to murine cells (Walczak et al, 1999).
Serum protein and albumin were measured using human reagent, Cobas C111, fully automated clinical analyzers, Diagnostics Roche, India, according to the instruction of the supplier.
The cells were resuspended in 90 μL of washing buffer and were preblocked with FcR Block (human) reagent (Miltenyi) for 10 min at room temperature in the dark.
Serum liver enzymes, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP), were measured using human reagent, Cobas C111, fully automated clinical analyzers, Diagnostics Roche, India, according to the instruction of the supplier.
This step was necessary to block residual anti-rat activity of the anti-human reagent before adding labelled rat anti-mouse antibodies for the specific markers [IgE, CD19, F4/80, CD49b (DX5), Gr-1, CD3 and CD11b].
Although a number of human immunological reagents such as monoclonal antibodies (mAb) and cytokines have been shown to cross-react with the farmed ruminant species (cattle, sheep and goats), a greater degree of cross-reactivity is found for reagents specifically developed against ruminant species.
Our data indicate the general mechanism of action for a new class of human immunotherapeutic reagents suitable for the treatment of cancer.
Recent advances in the technology of monoclonal antibody production provide the means to generate human antibody reagents and reintroduce antibody therapies, while avoiding the toxicities associated with serum therapy.
Our data highlight the properties of a new class of human immunotherapeutic reagents for the treatment of cancer, combining the selectivity of the binding component and the cytotoxicity of MAP that is specific towards proliferating cancer cells.
